Your best source on finance and banking news from Australia
Provided by AGP
AGP Picks
View all
Perspectify News
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
As featured in:
@ Journalists!
Join
Press releases
Publish your press release
May. 9, 2026
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
GlobeNewswire, Inc.
Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer...
May. 6, 2026
Australia Bondi Beach Attack Suspect May Face Additional Charges
MENAFN
World and Middle East business and financial news, Stocks, Currencies, Market Data, Research, Weather and other data.
May. 7, 2026
Australia LNG Giants to Reserve 20 Percent of Gas for Domestic Market
MENAFN
World and Middle East business and financial news, Stocks, Currencies, Market Data, Research, Weather and other data.
May. 8, 2026
IMMP Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit
GlobeNewswire, Inc.
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, 2026, a class action was filed on behalf of all...
May. 8, 2026
GEMI 10-DAY DEADLINE: Lawsuit Alleges IPO Documents Concealed Impending "Corporate Pivot" and Executive Turmoil - Gemini Space Station Investors Face Losses – Hagens Berman
GlobeNewswire, Inc.
SAN FRANCISCO, May 08, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Gemini Space Station, Inc. (NASDAQ: GEMI) and its top...
May. 8, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire, Inc.
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring...
Video Stories
Discover Affinity Group Publishing
Sign up for:
Australia Banking Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
